Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer

Prof Ignace Vergote - UZ Leuven, Leuven, Belgium
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer ( Prof Ignace Vergote - UZ Leuven, Leuven, Belgium )
7 Nov 2023

Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in PFS for locally advanced cervical cancer

Prof Domenica Lorusso - Fondazione IRCCS National Cancer Institute, Milan, Italy
Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in PFS for locally advanced cervical cancer ( Prof Domenica Lorusso - Fondazione IRCCS National Cancer Institute, Milan, Italy )
7 Nov 2023

Gynaecological Cancers

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
Gynaecological Cancers ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
7 Nov 2023

Atezolizumab with platinum-based CT and niraparib show no improvement in survival for rOC

Dr Antonio Gonzalez Martin - Cancer Center Clínica Universidad de Navarra, Madrid, Spain
Atezolizumab with platinum-based CT and niraparib show no improvement in survival for rOC ( Dr Antonio Gonzalez Martin - Cancer Center Clínica Universidad de Navarra, Madrid, Spain )
31 Oct 2023

Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer

Dr Mary McCormack - University College Hospital, London, UK
Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer ( Dr Mary McCormack - University College Hospital, London, UK )
23 Oct 2023

Durvalumab addition to chemo shows endometrial cancer benefit

Prof Shannon Westin - University of Texas MD Anderson Cancer Center, Houston, USA
Durvalumab addition to chemo shows endometrial cancer benefit ( Prof Shannon Westin - University of Texas MD Anderson Cancer Center, Houston, USA )
21 Oct 2023

Part 6: Which different PARP inhibitors are available

Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK
Part 6: Which different PARP inhibitors are available ( Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK )
5 Sep 2023

Part 7: Similarities and Differences

Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK
Part 7: Similarities and Differences ( Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK )
5 Sep 2023

Part 8: How PARP inhibitors are being used now

Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK
Part 8: How PARP inhibitors are being used now ( Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK )
5 Sep 2023

Part 9: What PARP inhibitors mean for the future and what to look out for

Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK
Part 9: What PARP inhibitors mean for the future and what to look out for ( Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK )
5 Sep 2023

The case for investing in women's cancers in Asia Pacific

Dr Heather White - Executive Director, TogetHER for Health
The case for investing in women's cancers in Asia Pacific ( Dr Heather White - Executive Director, TogetHER for Health )
4 Sep 2023

Nigeria solidarity support fund and the annual youth engagement campaign on HPV

Dr Fejiro Chinye-Nwoko - CEO, Nigeria Solidarity Support Fund, Lagos, Nigeria
Nigeria solidarity support fund and the annual youth engagement campaign on HPV ( Dr Fejiro Chinye-Nwoko - CEO, Nigeria Solidarity Support Fund, Lagos, Nigeria )
25 Aug 2023